Lifeboat Foundation

High-grade gliomas functionally remodel neural circuits in the human brain, promoting tumour progression and impairing cognition.

CHICAGO, May 3 (Reuters) — An experimental Alzheimer’s drug developed by Eli Lilly and Co (LLY.N) slowed cognitive decline by 35% in a late-stage trial, the company said on Wednesday, providing what experts say is the strongest evidence yet that removing sticky amyloid plaques from the brain benefits patients with the fatal disease.

Lilly’s drug, donanemab, met all goals of the trial, the company said. It slowed progression of Alzheimer’s by 35% compared to a placebo in 1,182 people with early-stage disease whose brains had deposits of two key Alzheimer’s proteins, beta amyloid as well as intermediate levels of tau, a protein linked with disease progression and brain cell death.

The study also evaluated the drug in 552 patients with high levels of tau and found that when both groups were combined, donanemab slowed progression by 29% based on a commonly used scale of dementia progression known as the Clinical Dementia Rating Scale (CDR-SB).

In a recent article published in the journal Nature Communications, researchers performed a large cross-sectional study to profile gut microbiota dysbiosis across prodromal and early stages of Parkinson’s disease (PD), REM sleep behavior disorder (RBD), first-degree relatives of RBD (RBD-FDR), and healthy controls.

Study: Gut microbiome dysbiosis across early Parkinson’s disease, REM sleep behavior disorder and their first-degree relatives. Image Credit: Anatomy Image / Shutterstock.

Magenta Medical — an Israeli company developing what it bills as “the world’s smallest heart pump” — closed a $55 million financing round on Wednesday.

The round was led by OrbiMed, with participation from New Enterprise Associates, Pitango and Alive Israel HealthTech Fund. Magenta did not disclose how much the company has raised to date.

The new funding will be used primarily to help the medtech company attain FDA approval for its flagship product — a percutaneous left ventricular assist device called Elevate.

An effort led by researchers in the Perelman School of Medicine at the University of Pennsylvania has developed a new risk model for cardiovascular disease in CKD patients. The researchers say it is more accurate than current methods of measuring cardiac risk in these individuals.

A paper about the research was published in European Heart Journal.

Today, the National Oceanic and Atmospheric Administration announced that it will be signing a new research agreement with Proteus Ocean Group, which has been drawing up ambitious plans to build a roomy underwater research facility that can host scientists for long stays while they study the marine environment up close.

The facility, called Proteus, is the brainchild of Fabien Cousteau, the grandson of Jacques Cousteau.

“On PROTEUS™ we will have unbridled access to the ocean 24/7, making possible long-term studies with continuous human observation and experimentation,” Cousteau, founder of Proteus Ocean Group, said in a press release. “With NOAA’s collaboration, the discoveries we can make — in relation to climate refugia, super corals, life-saving drugs, micro environmental data tied to climate events and many others — will be truly groundbreaking. We look forward to sharing those stories with the world.”

Our research found that concussion was associated with increased functional connectivity between the thalamus and the rest of the brain very shortly after injury, when compared to 76 healthy control subjects.

In other words, the thalamus was trying to communicate more as a result of the injury. This was despite routine MRI and CT imaging showing no structural changes in the brain.

While many of us would assume that more connectivity in the brain is a good thing, research looking at more severe head injuries indicates that greater connectivity between brain regions might actually be a sign of the brain trying to compensate and offset damage across the brain.

AUSTIN, Texas — Scientists at the University of Texas at Austin have created an artificial intelligence (AI) tool that can turn people’s brain activity into written text. This technology might help those who can’t physically speak, like stroke patients, communicate again.

Given the rise of chat gpt and its volumes of knowledge bases there is a new chat bot that is aiding mental health care and therapy 😀

When it comes to mental health, the main focus is on the patient and how to provide the best care possible. But with the rising demand for mental health services, it’s increasingly difficult for clinicians to address the individual needs of their patients and meet the growing demand for mental health services. This is where ChAT-GPT, or Conversational Artificial intelligence-based Therapy for Generalized Psychological Treatment, comes in.

Chat-GPT is an AI-based therapy that uses natural language processing (NLP) and conversational AI to help therapists provide more personalized and effective mental health care and therapy. This new technology allows mental health professionals to provide real-time and personalized care to their patients in a way that is tailored to their needs and preferences. In this article, we will discuss the key features of Chat-GPT and how it is helping improve mental health care and therapy.

Chat-GPT is a type of AI-based therapy developed by researchers at Albert Einstein College of Medicine. It is a conversational AI-based therapy designed to help clinicians diagnose mental health issues. Chat-GPT uses natural language processing (NLP) to understand the patient’s conversations and provide personalized care and therapy.

Continue reading “The Role of Chat-GPT in Improving Mental Health Care and Therapy” »